Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter
YouTube

32° Cloudy
- Broken Bow, NE (68822)
  Today
  
  Cloudy skies. High 46F. Winds SSE at 10 to 20 mph..
  
  Tonight
  
  Areas of fog. Low near 30F. Winds S at 5 to 10 mph.
  
  Updated: March 2, 2026 @ 10:33 am
- Full Forecast

Site search

Home
News
- Local News
Sports
Obituaries
Photos
Videos
e-Edition
Classifieds
- Legal Notices
Business Directory

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Merck Kgaa Spns/Adr (OP:MKKGY)

29.60 -0.82 (-2.70%)

Streaming Delayed Price Updated: 12:59 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck Kgaa Spns/Adr

< Previous 1 2 Next >

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗

October 17, 2025

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Via Benzinga

EMD Serono, CVS Health To Partner On TrumpRx Fertility Program Launching In 2026 ↗

October 17, 2025

Trump and EMD Serono strike a deal to cut fertility drug costs, expand U.S. manufacturing, and launch the TrumpRx Fertility program in 2026.

Via Benzinga

Topics Government

Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts ↗

August 11, 2025

Engine Capital, holding a 3% stake in Avantor, urges the board to pursue a turnaround or sale, citing years of underperformance, missed targets, and lost market share.

Via Benzinga

Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support

July 22, 2025

From Crown Bioscience

Via JCN Newswire

Germany's Merck To Launch Semiconductor Base In China ↗

May 31, 2022

Via Benzinga

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics ↗

February 11, 2025

Merck KGaA is in advanced talks to acquire SpringWorks, whose portfolio could bolster Merck's oncology business amid patent expirations and competition.

Via Benzinga

Topics Intellectual Property

GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗

January 13, 2025

GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.

Via Benzinga

Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition ↗

December 12, 2023

Pfizer Inc (NYSE: PFE)

Via Benzinga

Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗

December 06, 2023

Merck KGaA (OTC: MKGAF) (OTC:

Via Benzinga

Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors ↗

September 26, 2023

Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.

Via Benzinga

Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 ↗

August 03, 2023

Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported

Via Benzinga

Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗

July 26, 2023

The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen

Via Benzinga

Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation ↗

June 20, 2023

RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,

Via Benzinga

Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions ↗

April 18, 2023

Via Benzinga

FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study ↗

April 12, 2023

Via Benzinga

Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗

March 27, 2023

Via Benzinga

Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗

March 23, 2023

Via Benzinga

With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics ↗

January 20, 2023

Via Benzinga

PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment ↗

January 03, 2023

Via Benzinga

Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗

December 23, 2022

Via Benzinga

SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19 ↗

October 19, 2022

Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger

Via Benzinga

Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug ↗

October 19, 2022

The French court is reportedly investigating Germany-based Merck KGaA (OTC: MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox.

Via Benzinga

PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers ↗

October 11, 2022

Via Benzinga

TSM Looks To Hire Over 8,000 People In 2022 ↗

January 24, 2022

Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge, Financial...

Via Benzinga

Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing ↗

January 21, 2022

Amid continued questions about the profitability and the competitive advantages of Palantir in a crowded field, PLTR stock remains a sell.

Via InvestorPlace

The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings ↗

November 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...

Via Benzinga

GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact ↗

September 30, 2021

Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said...

Via Benzinga

Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study ↗

September 21, 2021

Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE...

Via Benzinga

Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial ↗

August 24, 2021

Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the...

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Business
Entertainment
Local Events
Obituaries
Multimedia
Online Features

Services

Subscription Services
Pay Your Bill
Classifieds
Promote Your Event
Email Alerts
Place an Ad
Rack Locations
Search
Weather

custercountychief.com
311 South 10th Avenue
Broken Bow, NE 68822
Phone: 308-872-2471
Email: publisher@custercountychief.com

Facebook
Twitter
YouTube

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Broken Bow, NE (68822)

Today

Tonight

Merck Kgaa Spns/Adr (OP:MKKGY)

All News about Merck Kgaa Spns/Adr

Sections

Services

Follow Us